Antibiotics damage the colonic mucus barrier in a microbiota-independent manner
Science Advances,
Год журнала:
2024,
Номер
10(37)
Опубликована: Сен. 11, 2024
Antibiotic
use
is
a
risk
factor
for
development
of
inflammatory
bowel
diseases
(IBDs).
IBDs
are
characterized
by
damaged
mucus
layer,
which
does
not
separate
the
intestinal
epithelium
from
microbiota.
Here,
we
hypothesized
that
antibiotics
affect
integrity
barrier,
allows
bacterial
penetrance
and
predisposes
to
inflammation.
We
found
antibiotic
treatment
led
breakdown
colonic
barrier
penetration
bacteria
into
layer.
Using
fecal
microbiota
transplant,
RNA
sequencing
followed
machine
learning,
ex
vivo
secretion
measurements,
germ-free
mice,
determined
induce
endoplasmic
reticulum
stress
in
colon
inhibits
microbiota-independent
manner.
This
antibiotic-induced
flaw
translocation
microbial
antigens
circulation,
exacerbation
ulcerations
mouse
model
IBD.
Thus,
might
predispose
inflammation
impeding
production.
Язык: Английский
Commensal fungi, a force to be reckoned with
Cell Host & Microbe,
Год журнала:
2025,
Номер
33(1), С. 6 - 8
Опубликована: Янв. 1, 2025
Язык: Английский
Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay
Frontiers in Microbiology,
Год журнала:
2025,
Номер
16
Опубликована: Март 25, 2025
Fecal
microbiota
transplantation
(FMT)
represents
a
therapeutic
approach
that
directly
regulates
the
gut
of
recipients,
normalizes
its
composition
and
reaping
rewards.
Currently,
in
addition
to
general
application
treating
Clostridium
difficile
(
C.
)
infection
(CDI),
FMT
treatment
has
also
been
extended
fields
other
gastrointestinal
diseases,
infections,
gut-liver
or
gut-brain
axis
disorders,
metabolic
diseases
cancer,
etc.
Prior
FMT,
rigorous
donor
screening
is
essential
reduce
occurrence
adverse
events.
In
addition,
it
imperative
evaluate
whether
recipient
can
safely
effectively
undergo
treatment.
However,
efficacy
influenced
by
complex
interactions
between
recipient,
degree
engraftment
not
necessarily
positively
related
with
success
rate
FMT.
Furthermore,
an
increasing
number
novel
factors
affecting
outcomes
are
being
identified
recent
clinical
trials
animal
experiments,
broadening
our
understanding
This
article
provides
comprehensive
review
scenarios
influencing
safety
from
aspects
both
donors
summarizes
how
these
emerging
regulatory
be
combined
predict
patients
undergoing
Язык: Английский
The Estonian Biobank’s journey from biobanking to personalized medicine
Nature Communications,
Год журнала:
2025,
Номер
16(1)
Опубликована: Апрель 5, 2025
Abstract
Large
biobanks
have
set
a
new
standard
for
research
and
innovation
in
human
genomics
implementation
of
personalized
medicine.
The
Estonian
Biobank
was
founded
quarter
century
ago,
its
biological
specimens,
clinical,
health,
omics,
lifestyle
data
been
included
over
800
publications
to
date.
What
makes
the
biobank
unique
internationally
is
translational
focus,
with
active
efforts
conduct
clinical
studies
based
on
genetic
findings,
explore
effects
return
results
participants.
In
this
review,
we
provide
an
overview
Biobank,
highlight
strengths
studying
variation
quantitative
phenotypes
health-related
traits,
development
methods
frameworks
bringing
into
clinic,
role
as
driving
force
implementing
medicine
national
level
beyond.
Язык: Английский
'Smart', microbiome-sparing antibacterial therapy with a focus on the novel Lolamicin: an overview
Infection,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 12, 2025
Antibiotic
resistance
(AR)
is
an
escalating
worldwide
health
emergency,
requiring
inventive
strategies
for
antibiotic
treatment.
This
review
examines
the
tactics
used
in
designing
smart
antibiotics,
with
a
specific
emphasis
on
mechanism
of
action
lolamicin,
newly
developed
microbiome-sparing
antibiotic.
We
recent
advances
development,
particularly
those
aiming
to
preserve
gut
microbiome
while
effectively
targeting
pathogens.
The
study
focuses
lolamicin's
selective
mechanism,
its
inhibition
LolCDE
complex
Gram-negative
bacteria.
Lolamicin
works
by
blocking
complex,
which
crucial
transporting
lipoproteins
Gramnegative
It
offers
significant
improvement
compared
conventional
antibiotics
and
other
microbiomesparing
options
safeguarding
reducing
development
resistance.
However,
limited
range
effectiveness
-
namely
against
certain
harmful
bacteria
such
as
Pseudomonas
aeruginosa
possibility
becoming
resistant
it,
remain
areas
concern.
presents
hopeful
resolution
selectively
attacking
leaving
beneficial
flora
unharmed.
Further
investigation
rigorous
clinical
testing
are
essential
fully
harness
promise
confirm
long-term
utility
combating
Язык: Английский
Living on the edge: Mucus-associated microbes in the colon
Mucosal Immunology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
The
colonic
mucus
layer
acts
as
a
physicochemical
barrier
to
pathogen
invasion
and
habitat
for
mucus-associated
microbes.
This
mucosal
microbiome
plays
crucial
role
in
moderating
production,
maintaining
integrity,
shaping
the
host
immune
response.
However,
unchecked
mucin
foraging
may
render
vulnerable
disease.
To
better
understand
these
dynamics
layer,
it
is
essential
advance
fundamental
knowledge
on
how
commensals
bind
utilize
well
their
interactions
with
both
microbial
neighbors.
We
present
an
overview
of
approaches
surveying
bacteria
assessing
mucin-utilizing
capacity,
alongside
discussion
limitations
existing
methods.
Additionally,
we
highlight
diet
secretory
immunoglobulin
A
interact
bacterial
community
colon.
Insights
into
this
subset
can
guide
therapeutic
strategies
optimally
support
modulate
integrity.
Язык: Английский
Diverse landscape of genomic research within the Estonian Biobank
Human Molecular Genetics,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 2, 2025
Язык: Английский
Induction of intercrypt goblet cells upon bacterial infection: a promising therapeutic target to restore the mucosal barrier
Gut Microbes,
Год журнала:
2024,
Номер
16(1)
Опубликована: Ноя. 14, 2024
Intestinal
mucins
play
a
crucial
role
in
the
mucosal
barrier,
serving
as
body's
initial
defense
against
microorganisms.
However,
how
host
regulates
secretion
and
glycosylation
of
these
response
to
bacterial
invasion
remains
unclear.
Our
study
demonstrates
that
when
exposed
Streptococcus
gallolyticus
(SGG),
gut
pathobiont,
mucosa
promptly
adjusts
behavior
specialized
goblet
cells
(GCs)
located
middle
crypts.
A
subset
undergoes
remodeling,
becoming
intercrypt
(icGCs),
which
do
not
detach
from
surface
but
instead
migrate
along
spaces
while
secreting
mucus
impermeable
pathogens.
Significantly,
non-piliated
SGG
mutant
unable
bind
fails
induce
icGCs,
allowing
its
translocation
through
submucosa.
Interestingly,
closely
related
nonpathogenic
bacterium,
SGM,
able
mucus,
also
triggers
differentiation
GCs
into
icGCs.
This
discovery
opens
new
avenues
for
treating
patients
with
"leaky
gut"
observed
intestinal
diseases
such
inflammatory
bowel
metabolic
disorders,
history
repeated
antibiotic
use.
Utilizing
mucus-adherent
probiotics
icGCs
represents
promising
strategy
reinforcing
barrier.
Язык: Английский